Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 15, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase transaction:
- Shares Purchased: 600,000 ordinary shares of 25 pence each.
- Purchase Price: 1,483.4964 pence per share.
- Transaction Date: February 15, 2007.
Material Changes
Following the repurchase, the company's Treasury share holdings increased to 252,247,678 shares. The total number of shares in issue (excluding Treasury shares) stands at 5,751,359,336, which represents the total voting rights in the company.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,751,359,336) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count of 252,247,678.
- Note that this filing is a notification of a specific share buyback and does not contain periodic financial performance results.